Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"

Next Previous
X
Search
Trial Profile

Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary) ; Maraviroc (Primary) ; Antibacterials; Dexamethasone; Enoxaparin sodium
  • Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms COMVIVIR

    • Most Recent Events

    • 31 May 2022 Status changed from recruiting to discontinued as no more patients complying the selection criteria were available for recruitment]
    • 09 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Aug 2022.
    • 09 Mar 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top